DOCSLIB.ORG

Brain CYP2D6 and Its Role in Neuroprotection Against Parkinson's

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Brain CYP2D6 and Its Role in Neuroprotection Against Parkinson's Brain CYP2D6 and its role in neuroprotection against Parkinson’s disease by Amandeep Mann A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Graduate Department of Pharmacology and Toxicology University of Toronto © Copyright by Amandeep Mann 2011 Brain CYP2D6 and its role in neuroprotection against Parkinson’s disease Amandeep Mann Doctor of Philosophy, 2011 Graduate Department of Pharmacology and Toxicology University of Toronto Abstract The enzyme CYP2D6 can metabolize many centrally acting drugs and endogenous neural compounds (e.g. catecholamines); it can also inactivate neurotoxins such as 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP), 1,2,3,4-tetrahydroisoquinoline (TIQ) and β- carbolines that have been associated with Parkinson’s disease (PD). CYP2D6 is ideally situated in the brain to inactivate these neurotoxins. The CYP2D6 gene is also highly polymorphic, which leads to large variation in substrate metabolism. Furthermore, CYP2D6 genetically poor metabolizers are known to be at higher risk for developing PD, a risk that increases with exposure to pesticides. Conversely, smokers have a reduced risk for PD and smokers are suggested to have higher brain CYP2D6 levels. Our studies furthered the characterization and involvement of CYP2D6 in neuroprotection against PD. METHODS: We investigated the effects of CYP2D6 inhibition on MPP+-induced cell death in SH-SHY5Y human neuroblastoma cells. We compared levels of brain CYP2D6, measured by western blotting, between human smokers and non-smokers, between African Green monkeys treated with saline or nicotine, and between PD cases and controls. In addition, we assessed changes in human brain CYP2D6 expression with age. RESULTS: Blocking CYP2D6 activity in SH- SY5Y cells with four diverse inhibitors significantly increased MPP+-induced neurotoxicity. Smokers have higher brain CYP2D6 compared to non-smokers. In monkeys, basal expression of CYP2D6 varied across brain regions and was increased by chronic nicotine treatment in II select regions (notably the basal ganglia) and specific cell types. Expression of human brain CYP2D6 increased from fetal to 80 years of age in the frontal cortex; the influence of age on CYP2D6 expression was brain region specific. Compared to age-matched controls, PD cases had ~40% lower CYP2D6 levels in the frontal cortex, cerebellum and hippocampus consistent with lower CYP2D6 increasing the risk for PD. In the caudate and substantia nigra, CYP2D6 levels were similar between PD case and controls using Western blotting. This is likely due to the increase in CYP2D6-expressing astrocytes and much higher cellular CYP2D6 in PD affected areas as observed with immunocytochemical staining. CONCLUSIONS: Brain CYP2D6 can meaningfully inactivate neurotoxins, and it can be increased by nicotine in brain regions of interest to PD. These findings support the contention that higher brain CYP2D6 is protective and lower levels may contribute to increased risk for PD. III Acknowledgments First and foremost, I would like to thank my supervisor Dr. Rachel F. Tyndale for her support, guidance and mentorship during my Ph.D. I am grateful for all the opportunities she provided that allowed me to grow as a student and as a professional. She inspired me to always be learning, thinking, applying and questioning science. Her hard work, dedication and continuous encouragement shaped me to become a better student and scientist. I am very grateful to the excellent Ph.D. Committee Members Dr. Jose Nobrega and Dr. James Wells, who contributed their time, knowledge and expertise. Their guidance and constructive criticism was very helpful in bringing the research within this thesis together. I would also like to thank my all of my friends and colleagues, who provided their support, time, knowledge, advice and technical expertise during my Ph.D. This especially includes Ewa Hoffmann, Charmaine Ferguson, Jibran Khokhar, Sharon Miksys, Daniel Hanna and Andy Zhu. This accomplishment was that much more achievable and enjoyable with the love from my dearest friends Helena Mistry, Nael Al Koudsi, Vaneeta Verma, Jassi Lachhar-Dugha and my best friend Arun Dhanota. Last but not least, I would like to thank my family for their love, support and continuous encouragement. I am sincerely thankful to my parents' hard work, patience and understanding, without which I would not have had the opportunities I did in my life. I am appreciative of my Grandfather's wisdom and advice that helped me gain perspective and make sense of things during challenging times. The constant encouragement provided by my sister-in-law Jasmine and brother Kamal definitely made this goal much easier to achieve. I am also very thankful to my niece Nayha for brightening my days with her smiles, hugs, kisses and paintings when I needed it the most. Lastly, I would like to thank my Grandmother for her love and support. As she had been very excited to see me complete my Ph.D., I dedicate this thesis in her loving memory. IV Table of Contents Abstract ............................................................................................................................................... II Acknowledgments........................................................................................................................... IV Table of Contents...............................................................................................................................V List of Table......................................................................................................................................VII List of figures ................................................................................................................................. VIII Summary of abbreviation............................................................................................................. IX Section I: Introduction.....................................................................................................................1 Statement of Research Problem............................................................................................................. 1 Review of the literature............................................................................................................................ 3 1. Cytochromes P450 2D6 (CYP2D6).................................................................................................... 3 1.1 Cytochromes P450 ..............................................................................................................................................3 1.2 CYP2D6 substrates..............................................................................................................................................4 1.3 CYP2D6 inhibitors...............................................................................................................................................7 1.4 CYP2D6 regulation........................................................................................................................................... 10 1.5 CYP2D6 genetic variation.............................................................................................................................. 11 1.5.A CYP2D pseudogenes..................................................................................................................................................14 1.5.B Interethnic variability CYP2D6.............................................................................................................................14 1.5.C CYP2D6 genetic associations to health risk.....................................................................................................15 1.6 CYP2D expression in different species.................................................................................................... 16 1.6.A CYP2D in rodents .......................................................................................................................................................16 1.6.B CYP2D in non-human primates............................................................................................................................18 2. Brain Cytochromes P450 ...................................................................................................................19 2.1 Brain CYP expression...................................................................................................................................... 19 2.1.A Brain CYP activity.......................................................................................................................................................20 2.1.B Brain CYP regulation.................................................................................................................................................21 2.2 Brain CYP2D6..................................................................................................................................................... 22 2.2.A CYP2D6 CNS expression..........................................................................................................................................22 2.2.B CYP2D6 CNS function ...............................................................................................................................................23 2.2.C Brain CYP2D6 regulation ........................................................................................................................................26
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar
    USOO896.9514B2 (12) United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar. 3, 2015 (54) AGONISTS OF GUANYLATECYCLASE 5,879.656 A 3, 1999 Waldman USEFUL FOR THE TREATMENT OF 36; A 6. 3: Watts tal HYPERCHOLESTEROLEMIA, 6,060,037- W - A 5, 2000 Waldmlegand et al. ATHEROSCLEROSIS, CORONARY HEART 6,235,782 B1 5/2001 NEW et al. DISEASE, GALLSTONE, OBESITY AND 7,041,786 B2 * 5/2006 Shailubhai et al. ........... 530.317 OTHER CARDOVASCULAR DISEASES 2002fOO78683 A1 6/2002 Katayama et al. 2002/O12817.6 A1 9/2002 Forssmann et al. (75) Inventor: Kunwar Shailubhai, Audubon, PA (US) 2003,2002/0143015 OO73628 A1 10/20024, 2003 ShaubhaiFryburg et al. 2005, OO16244 A1 1/2005 H 11 (73) Assignee: Synergy Pharmaceuticals, Inc., New 2005, OO32684 A1 2/2005 Syer York, NY (US) 2005/0267.197 A1 12/2005 Berlin 2006, OO86653 A1 4, 2006 St. Germain (*) Notice: Subject to any disclaimer, the term of this 299;s: A. 299; NS et al. patent is extended or adjusted under 35 2008/0137318 A1 6/2008 Rangarajetal.O U.S.C. 154(b) by 742 days. 2008. O151257 A1 6/2008 Yasuda et al. 2012/O196797 A1 8, 2012 Currie et al. (21) Appl. No.: 12/630,654 FOREIGN PATENT DOCUMENTS (22) Filed: Dec. 3, 2009 DE 19744O27 4f1999 (65) Prior Publication Data WO WO-8805306 T 1988 WO WO99,26567 A1 6, 1999 US 2010/O152118A1 Jun. 17, 2010 WO WO-0 125266 A1 4, 2001 WO WO-02062369 A2 8, 2002 Related U.S.
    [Show full text]
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers
    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
    [Show full text]
  • NTP-CERHR Expert Panel Report on the Reproductive and Developmental Toxicity of Amphetamine and Methamphetamine
    Published 2005 Wiley-Liss, Inc.w Birth Defects Research (Part B) 74:471–584 (2005) NTP-CERHR Expert Panel Report on the Reproductive and Developmental Toxicity Of Amphetamine and Methamphetamine Mari Golub,1 Lucio Costa,2 Kevin Crofton,3 Deborah Frank,4 Peter Fried,5 Beth Gladen6 Rogene Henderson,7 Erica Liebelt,8 Shari Lusskin,9 Sue Marty,10 Andrew Rowland11 John Scialli12 and Mary Vore13 1California Environment Protection Agency, Sacramento, California 2University of Washington, Seattle, Washington 3U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 4Boston Medical Center, Boston, Massachusetts 5Carleton University, Ottawa, Ontario 6National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 7Lovelace Respiratory Research Institute, Albuquerque, New Mexico 8University of Alabama at Birmingham School of Medicine, Birmingham, Alabama 9New York University School of Medicine, New York, New York 10The Dow Chemical Company, Midland, Michigan 11University of New Mexico, Albuquerque, New Mexico 12Phoenix, Arizona 13University of Kentucky, Lexington, Kentucky PREFACE studies indexed before December 31, 2004. References were also identified from databases such as REPRO- The National Toxicology Program (NTP) and the TOXs, HSDB, IRIS, and DART and from report National Institute of Environmental Health Sciences bibliographies. (NIEHS) established the NTP Center for the Evaluation This evaluation resulted from the efforts of a 13- of Risks to Human Reproduction (CERHR) in June 1998. member panel of government and non-government The purpose of the Center is to provide timely, unbiased, scientists that culminated in a public expert panel scientifically sound evaluations of human and experi- meeting held January 10–12, 2005. This report is a mental evidence for adverse effects on reproduction and product of the Expert Panel and is intended to (1) development caused by agents to which humans may be interpret the strength of scientific evidence that exposed.
    [Show full text]
  • Inhibition of Monoamine Oxidase in 5
    Br. J. Pharmac. (1985), 85, 683-690 Inhibition ofmonoamine oxidase in 5- hydroxytryptaminergic neurones by substitutedp- aminophenylalkylamines Anna-Lena Ask, Ingrid Fagervall, L. Florvall, S.B. Ross1 & Susanne Ytterborn Research Laboratories, Astra Likemedel AB, S-151 85 Si3dertilje, Sweden 1 A series ofsubstituted p-aminophenethylamines and some related compounds were examined with regards to the inhibition ofmonoamine oxidase (MAO) in vivo inside and outside 5-hydroxytryptamin- ergic neurones in the rat hypothalamus. This was recorded as the protection against the irreversible inhibition of MAO produced by phenelzine by determining the remaining deaminating activity in the absence and presence ofcitalopram using a low (0.1 yIM) concentration of ['4CJ-5-hydroxytryptamine (5-HT) as substrate. 2 Some ofthe phenethylamines were much more potent inside than outside the 5-hydroxytryptamin- ergic neurones. This neuronal selectivity was antagonized by pretreatment of the rats with norzimeldine, a 5-HT uptake inhibitor, which indicates that these compounds are accumulated in the 5-HT nerve terminals by the 5-HT pump. 3 Selectivity was obtained for compounds with dimethyl, monomethyl or unsubstituted p-amino groups. An isopropyl group appears to substitute for the dimethylamino group but with considerably lower potency. Compounds with 2-substitution showed selectivity for aminergic neurones and this effect decreased with increased size of the substituent. The 2,6-dichloro derivative FLA 365 had, however, no neuronal selective action but was a potent MAO inhibitor. Substitutions in the 3- and 5- positions decreased both potency and selectivity. 4 Prolongation ofthe side chain with one methylene group abolished the preference for the MAO in 5-hydroxytryptaminergic neurones although the MAO inhibitory potency remained.
    [Show full text]
  • Monoamine Oxidase Inhibitory Properties of Some Methoxylated and Alkylthio Amphetamine Derivatives Strucrure-Acfivity RELA TIONSHIPS Ma
    Biochemieal PhannaeoloR)'. Vol. 54. pp. 1361-1369, 1997. ISSN 0006-2952/97/$17.00 + 0.00 © 1997 Elsevier Scienee Ine. Al! rights reserved. PIl SOOO6-2952(97)00405·X ELSEVIER Monoamine Oxidase Inhibitory Properties of Some Methoxylated and Alkylthio Amphetamine Derivatives STRUcruRE-ACfIVITY RELA TIONSHIPS Ma. Cecilia Scorza,* Cecilia Carrau,* Rodolfo Silveira,* GemId Zapata,Torres,t Bruce K. Casselst and Miguel Reyes,Parada*t *DIVISIÓNBIOLOGíACELULAR,INSTITUTODEINVESTIGACIONESBIOLÓGICASCLEMENTeEsTABlE, CP 11600, MONTEVIOEO,URUGUAY;ANDtDEPARTAMENTODEQUíMICA, FACULTADDECIENCIAS,UNIVERSIDADDECHILE, SANTIAGO,CHILE ABSTRACT. The monoamine oxidase (MAO) inhibitory propenies of a series of amphetamine derivatives with difTerent substituents at or around rhe para position of the aromaric ring were evaluateJ. i¡, in viero stuJies in which a crude rar brain mirochllndrial suspension was used as rhe source of MAO, several compounds showed a srrong (ICS0 in rhe submicromolar range), selecrive, reversible, time-independenr, and concenrrarion-related inhibition of MAO-A. After i.p. injection, the compounds induced an inerease of serotonin and a decrease of j-hydroxyindoleacetic acid in the raphe nuclei and hippocampus, confinning rhe in virro results. The analysis of structure-activity relationships indicates rhat: molecules with amphetamine-Iike structure and different substitutions nn the aromaric ring are potentially MAO-A inhibitors; substituents at different positions of the aromatic ring moditY the porency but have litde inf1uence "n the selectiviry; substituents at rhe para position sllch as ,lmino, alkoxyl. halogens. or alkylthio produce a significant increase in rhe acrivity; the para-substituent musr be an e1ectron Jonor; hulky ~roups next to rhe para subsriruent Icad ro a Jecrease in the actÍ\'ityi ,ubstiruents loearcd ar posirions more Jistant ,m rhe aromaric ring havc less intluence anJ, even when the subsriruent is '1 halogen (CI, Br), an increase in rhe acrivity "f rhe cllmpound is llbtained.
    [Show full text]
  • Inhibitory Effects of Phytochemicals on Metabolic Capabilities of CYP2D6*1 and CYP2D6*10 Using Cell-Based Models in Vitro
    Acta Pharmacologica Sinica (2014) 35: 685–696 npg © 2014 CPS and SIMM All rights reserved 1671-4083/14 $32.00 www.nature.com/aps Original Article Inhibitory effects of phytochemicals on metabolic capabilities of CYP2D6*1 and CYP2D6*10 using cell-based models in vitro Qiang QU1, 2, Jian QU1, Lu HAN2, Min ZHAN1, Lan-xiang WU3, Yi-wen ZHANG1, Wei ZHANG1, Hong-hao ZHOU1, * 1Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Xiangya Hospital, Central South University, Changsha 410078, China; 2Xiangya Hospital, Central South University, Changsha 410008, China; 3Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, China Aim: Herbal products have been widely used, and the safety of herb-drug interactions has aroused intensive concerns. This study aimed to investigate the effects of phytochemicals on the catalytic activities of human CYP2D6*1 and CYP2D6*10 in vitro. Methods: HepG2 cells were stably transfected with CYP2D6*1 and CYP2D6*10 expression vectors. The metabolic kinetics of the enzymes was studied using HPLC and fluorimetry. Results: HepG2-CYP2D6*1 and HepG2-CYP2D6*10 cell lines were successfully constructed. Among the 63 phytochemicals screened, 6 compounds, including coptisine sulfate, bilobalide, schizandrin B, luteolin, schizandrin A and puerarin, at 100 μmol/L inhibited CYP2D6*1- and CYP2D6*10-mediated O-demethylation of a coumarin compound AMMC by more than 50%. Furthermore, the inhibition by these compounds was dose-dependent. Eadie-Hofstee plots demonstrated that these compounds competitively inhibited CYP2D6*1 and CYP2D6*10. However, their Ki values for CYP2D6*1 and CYP2D6*10 were very close, suggesting that genotype- dependent herb-drug inhibition was similar between the two variants.
    [Show full text]
  • M a P S • V O L U M E X I I I N U M B E R 2
    m a p s • v o l u m e x i i i n u m b e r 2 • w i n t e r 2 0 0 3 1 2 m a p s • v o l u m e x i i i n u m b e r 2 • w i n t e r 2 0 0 3 Divine Spark The cover of this MAPS bulletin is an image from visionary artist Alex Grey’s triptych Holy Fire, which was inspired by one of Alex’s early MDMA experiences. We thought it was an appropriate choice to ex- press our emotions at obtaining Institutional Review Board (IRB) approval for Dr. Mithoefer's MAPS-sponsored MDMA/PTSD study (see page 7). The rest of the images on this page and on the back cover are from the 2003 Burning Man Festival, at which MAPS provided psychedelic emergency services. (Article on page 28). In the photo above, members of the Fire Conclave open the festivities at the Burning of the Man, the climax of the week-long festival. The photo below depicts the more somber burning of the Temple of Honor, at which Burning Man participants remember loved ones by leaving notes and tokens inside. As the temple burned, MAPS president Rick Doblin threw in the fire the original copies of the last set of documents about protocol design issues exchanged between MAPS and the IRB. This symbolized his hopes that we would finally move beyond the paperwork of the approval process to the therapeutic work of the study itself.
    [Show full text]
  • Use of Hμrel Human Coculture System for Prediction of Intrinsic
    Article pubs.acs.org/molecularpharmaceutics Use of HμREL Human Coculture System for Prediction of Intrinsic Clearance and Metabolite Formation for Slowly Metabolized Compounds Ia Hultman,*,†,‡ Charlotta Vedin,†,‡ Anna Abrahamsson,§ Susanne Winiwarter,† and Malin Darnell† † § Drug Safety & Metabolism and RIA iMed DMPK, AstraZeneca R&D Gothenburg, 431 83 Mölndal, Sweden *S Supporting Information ABSTRACT: Design of slowly metabolized compounds is an important goal in many drug discovery projects. Standard hepatocyte suspension intrinsic clearance (CLint) methods can μ only provide reliable CLint values above 2.5 L/min/million cells. A method that permits extended incubation time with maintained performance and metabolic activity of the in vitro system is warranted to allow in vivo clearance predictions and metabolite identification of slowly metabolized drugs. The aim of this study was to evaluate the static HμREL coculture of human hepatocytes with stromal cells to be set up in-house as a standard method for fi in vivo clearance prediction and metabolite identi cation of slowly metabolized drugs. Fourteen low CLint compounds were incubated for 3 days, and seven intermediate to high CLint compounds and a cocktail of cytochrome P450 (P450) marker substrates were incubated for 3 h. In vivo clearance was predicted for 20 compounds applying the regression line approach, and HμREL coculture predicted the human intrinsic clearance for 45% of the drugs within 2-fold and 70% of the drugs within 3-fold μ of the clinical values. CLint values as low as 0.3 L/min/million hepatocytes were robustly produced, giving 8-fold improved ff sensitivity of robust low CLint determination, over the cuto in hepatocyte suspension CLint methods.
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]
  • Hallucinogen May Cure Drug Addictions (PDF)
    <<Back Hallucinogen May Cure Drug Addiction Posted: February 18, 2004 at 8:58 p.m. BAY AREA (KRON) -- Drug addiction has been the plague of modern America. But that could now change forever. What started as a rumor may now actually be an incredible breakthrough in the battle against addictions of all kinds. Ibogaine has a number of strikes against it: It doesn't come from a modern laboratory, but from an ancient plant. It was discovered not by a scientist, but by a heroin addict. It is mildly hallucinogenic and completely illegal in the United States. However, when it comes to curing addiction, a reputable scientist believes ibogaine is nothing short of a miracle. "I didn't believe it when I first heard about ibogaine. I thought it was something that needed to be debunked," admits Dr. Deborah Mash, professor of Neurology and Molecular and Cellular Pharmacology at University of Miami. Dr. Mash is one of the few scientists in the world to study ibogaine, a mild hallucinogen that comes from the root of a shrub found in West Africa and was rumored to have the amazing ability to help drug addicts kick their addiction. "This didn't come from the Salk Institute, this didn't come from the Scripps Institute. This came from a junkie who took a dose to get high himself. So the original observation came from the underground," says Dr. Mash. Observations from this particular underground are not likely to gain the respect of mainstream society, and ibogaine was no exception. That first report came in 1962.
    [Show full text]
  • Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews
    Supplementary Online Content Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. Published online April 27, 2016. doi:10.1001/jamacardio.2016.0218. eAppendix 1. Search Documentation Details eAppendix 2. Background, Methods, and Results of Systematic Review of Combination Drug Therapy to Evaluate for Potential Interaction of Effects eAppendix 3. PRISMA Flow Charts for Each Drug Class and Detailed Systematic Review Characteristics and Summary of Included Systematic Reviews and Meta-analyses eAppendix 4. List of Excluded Studies and Reasons for Exclusion This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eAppendix 1. Search Documentation Details. Database Organizing body Purpose Pros Cons Cochrane Cochrane Library in Database of all available -Curated by the Cochrane -Content is limited to Database of the United Kingdom systematic reviews and Collaboration reviews completed Systematic (UK) protocols published by by the Cochrane Reviews the Cochrane -Only systematic reviews Collaboration Collaboration and systematic review protocols Database of National Health Collection of structured -Curated by Centre for -Only provides Abstracts of Services (NHS) abstracts and Reviews and Dissemination structured abstracts Reviews of Centre for Reviews bibliographic
    [Show full text]